These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25552777)

  • 1. Pharmacovigilance and tuberculosis: applying the lessons of thioacetazone.
    Falzon D; Hill G; Pal SN; Suwankesawong W; Jaramillo E
    Bull World Health Organ; 2014 Dec; 92(12):918-9. PubMed ID: 25552777
    [No Abstract]   [Full Text] [Related]  

  • 2. Further consequences of thioacetazone-induced cutaneous reactions.
    Lawn SD; Griffin GE
    Int J Tuberc Lung Dis; 2000 Jan; 4(1):92-3. PubMed ID: 10654652
    [No Abstract]   [Full Text] [Related]  

  • 3. Rebuttal: time to call a halt to emotions in the assessment of thioacetazone.
    Rieder HL; Enarson DA
    Tuber Lung Dis; 1996 Apr; 77(2):109-11. PubMed ID: 8762843
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of tuberculosis in developing countries.
    Pozniak A
    Lancet; 1995 Oct; 346(8982):1099. PubMed ID: 7564806
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of tuberculosis in developing countries.
    Elliott AM; Mwinga AG; Foster SD
    Lancet; 1995 Oct; 346(8982):1098-9. PubMed ID: 7564805
    [No Abstract]   [Full Text] [Related]  

  • 6. Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection.
    Elliott AM; Foster SD
    Tuber Lung Dis; 1996 Feb; 77(1):27-9. PubMed ID: 8733410
    [No Abstract]   [Full Text] [Related]  

  • 7. Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.
    Ghimire S; Bolhuis MS; Sturkenboom MG; Akkerman OW; de Lange WC; van der Werf TS; Alffenaar JW
    Eur Respir J; 2016 Jun; 47(6):1867-9. PubMed ID: 26989104
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe hypersensitivity reactions among HIV-seropositive patients with tuberculosis treated with thioacetazone.
    Wkly Epidemiol Rec; 1992 Jan; 67(1-2):1-3. PubMed ID: 1371055
    [No Abstract]   [Full Text] [Related]  

  • 9. Thioacetazone--a review.
    Leowski J
    Indian J Chest Dis Allied Sci; 1982; 24(2-3):184-9. PubMed ID: 6187675
    [No Abstract]   [Full Text] [Related]  

  • 10. [Characteristics of drug-induced hepatitis in patients with tuberculosis].
    Vil'derman AM
    Probl Tuberk; 1972; 50(5):59-63. PubMed ID: 4112966
    [No Abstract]   [Full Text] [Related]  

  • 11. Wrong drug used for tuberculosis.
    Kelly PM
    Int J Tuberc Lung Dis; 1997 Aug; 1(4):385. PubMed ID: 9432398
    [No Abstract]   [Full Text] [Related]  

  • 12. Side effects of drugs used to treat tuberculosis.
    Newton RW
    Scott Med J; 1975 Mar; 20(2):47-9. PubMed ID: 47648
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug regimen for tuberculosis without thiacetazone and streptomycin.
    Biddulph J
    Lancet; 1991 May; 337(8750):1174. PubMed ID: 1709250
    [No Abstract]   [Full Text] [Related]  

  • 14. 'Have we missed reporting adverse drug reactions under Revised National TB Control Programme?' - A mixed method study in Bengaluru, India.
    Krishnappa L; Gadicherla S; Chidambaram P; Anuradha HV; Somanna SN; Naik PR; Das A; Narasimhaiah S; Nagaraja SB
    Indian J Tuberc; 2020 Jan; 67(1):20-28. PubMed ID: 32192612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma.
    Watkins WM; Mungai M; Muhia DK; Mberu EK; Gathua S; Winstanley PA; Gilks CF; Nunn P
    Br J Clin Pharmacol; 1996 Feb; 41(2):160-2. PubMed ID: 8838444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiological evidence of peripheral nerve damage in patients treated with isoniazid.
    Bahemuka M; Kioy PM; Wanjama M; Wainaina CM
    East Afr Med J; 1982 Dec; 59(12):798-802. PubMed ID: 6191942
    [No Abstract]   [Full Text] [Related]  

  • 17. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
    Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya.
    van Gorkom J; Kibuga DK
    Tuber Lung Dis; 1996 Feb; 77(1):30-6. PubMed ID: 8733411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring for adverse events among patients on tuberculosis therapy.
    Michail D
    N S W Public Health Bull; 2013 Jul; 24(1):24-6. PubMed ID: 23849024
    [No Abstract]   [Full Text] [Related]  

  • 20. [Thiacetazone (Tb-1): recent experimental and clinical data].
    Grosset J; Benhassine M
    Bibl Tuberc; 1970; 26():107-53. PubMed ID: 4189928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.